Case Study: Nevro helps hedge funds make faster IPO decisions with Guidepoint expert insights

Nevro evaluates its IPO in 48 hours with Guidepoint

The customer, Nevro, a medical device manufacturer, faced the challenge of having hedge funds quickly evaluate the potential of its Senza HF10 System spinal cord stimulator ahead of its IPO. These funds needed real-world insights on the new device to make an informed investment decision amidst stiff competition. They engaged the vendor, Guidepoint, to provide expert consultations.

Guidepoint's solution was to rapidly connect multiple hedge fund clients with a slate of highly qualified medical experts, including neurologists and neurosurgeons with direct experience in spinal cord stimulation. As a result of this research, several funds were able to complete their analysis and make well-informed investment decisions within 48 hours of their request.

Nevro